S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Tilray Brands Absorbs HelloMD to Bolster Medical Cannabis Reach

Tilray Brands is moving to capture a larger share of the medical cannabis market through the acquisition of HelloMD, a digital platform specializing in telehealth consultations and patient engagement. The deal aims to bridge the gap between cultivation and consumer care, integrating clinical guidance directly into the company’s Canadian supply chain.

Tilray Brands Absorbs HelloMD to Bolster Medical Cannabis Reach

The transaction, for which financial details remain undisclosed, positions Tilray as the successful bidder in a court-supervised sale process. By absorbing HelloMD’s infrastructure, Tilray intends to build a vertically integrated ecosystem that connects its existing production capacity with physician-led patient education and product fulfillment. This move centralizes the patient experience, moving beyond simple distribution to offer a comprehensive medical support network.

Beyond current Canadian operations, the acquisition serves as a foundation for broader international growth. Management indicated that the platform’s digital framework provides a scalable model for entering wellness segments, specifically sleep support and pain management. These expansion efforts remain contingent on the evolving regulatory landscape in target markets, but the integration of HelloMD’s telehealth capabilities gives the company a functional blueprint for navigating those requirements.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!